80 FR 11449 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Investigational New Drug Applications
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 80, Issue 41 (March 3, 2015)
Food and Drug Administration
Federal Register Volume 80, Issue 41 (March 3, 2015)
| Page Range | 11449-11454 | |
| FR Document | 2015-04379 |
[Federal Register Volume 80, Number 41 (Tuesday, March 3, 2015)] [Notices] [Pages 11449-11454] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-04379] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-N-1721] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Investigational New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by April 2, 2015. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to [email protected]. All comments should be identified with the OMB control number 0910-0014. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected]. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Investigational New Drug (IND) Regulations--21 CFR Part 312 (OMB Control Number 0910-0014)--Extension FDA is requesting OMB approval for the reporting and recordkeeping requirements contained in FDA regulations entitled ``Investigational New Drug Application'' in part 312 (21 CFR part 312). Part 312 implements provisions of section 505(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) to issue regulations under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted. FDA is charged with implementing statutory requirements that drug products marketed in the United States be shown to be safe and effective, properly manufactured, and properly labeled for their intended uses. Section 505(a) of the FD&C Act provides that a new drug may not be introduced or delivered for introduction into interstate commerce in the United States unless FDA has previously approved a new drug application (NDA). FDA approves an NDA only if the sponsor of the application first demonstrates that the drug is safe and effective for the conditions prescribed, recommended, or suggested in the product's labeling. Proof must consist, in part, of adequate and well-controlled studies, including studies in humans, that are conducted by qualified experts. The IND regulations establish reporting requirements that include an initial application as well as amendments to that application, reports on significant revisions of clinical investigation plans, and information on a drug's safety or effectiveness. In addition, the sponsor is required to give FDA an annual summary of the previous year's clinical experience. Submissions are reviewed by medical officers and other Agency scientific reviewers assigned responsibility for overseeing the specific study. The IND regulations also contain recordkeeping requirements that pertain to the responsibilities of sponsors and investigators. The detail and complexity of these requirements are dictated by the scientific procedures and human subject safeguards that must be followed in the clinical tests of investigational new drugs. The IND information collection requirements provide the means by which FDA can monitor the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products, including the following: (1) Monitor the safety of ongoing clinical investigations; (2) determine whether the clinical testing of a drug should be authorized; (3) ensure production of reliable data on the metabolism and pharmacological action of the drug in humans; (4) obtain timely information on adverse reactions to the drug; (5) obtain information on side effects associated with increasing doses; (6) obtain information on the drug's effectiveness; (7) ensure the design of well-controlled, scientifically valid studies; and (8) obtain other information pertinent to determining whether clinical testing should be continued, and information related to the protection of human subjects. Without the information provided by industry as required under the IND regulations, FDA cannot authorize or monitor the clinical investigations which must be conducted prior to authorizing the sale and general use of new drugs. These reports enable FDA to monitor a study's [[Page 11450]] progress, to assure subject safety, to assure that a study will be conducted ethically, and to increase the likelihood that the sponsor will conduct studies that will be useful in determining whether the drug should be marketed and available for use in medical practice. There are two forms that are required under part 312: Form FDA-1571--``Investigational New Drug Application.'' A person who intends to conduct a clinical investigation submits this form to FDA. It includes the following information: (1) A cover sheet containing background information on the sponsor and investigator; (2) A table of contents; (3) An introductory statement and general investigational plan; (4) An investigator's brochure describing the drug substance; (5) A protocol for each planned study; (6) Chemistry, manufacturing, and control information for each investigation; (7) Pharmacology and toxicology information for each investigation; and (8) Previous human experience with the investigational drug. Form FDA-1572--``Investigator Statement.'' Before permitting an investigator to begin participation in an investigation, the sponsor must obtain and record this form. It includes background information on the investigator and the investigation, and a general outline of the planned investigation and the study protocol. FDA is requesting OMB approval for the following reporting and recordkeeping requirements in part 312. I. Reporting Requirements Section 312.2(e)--Requests for FDA advice on the applicability of part 312 to a planned clinical investigation. Section 312.6--Labeling of an investigational new drug. Estimates for the information collection in this requirement are included under Sec. 312.23(a)(7)(iv)(d). Section 312.8--Charging for investigational drugs under an IND. Section 312.10--Applications for waiver of requirements under part 312. As indicated in Sec. 312.10(a), estimates for the information collection in this requirement are included under Sec. Sec. 312.23 and 312.31. In addition, other waiver requests under Sec. 312.10 are estimated in table 1. Section 312.20(c)--Applications for investigations involving an exception from informed consent under Sec. 50.24 (21 CFR 50.24). Estimates for the information collection in this requirement are included under Sec. 312.23. Section 312.23--IND (content and format). Section 312.23(a)(1)--Cover sheet FDA-1571. Section 312.23(a)(2)--Table of Contents. Section 312.23(a)(3)--Investigational plan for each planned study. Section 312.23(a)(5)--Investigator's brochure. Section 312.23(a)(6)--Protocols--Phase 1, 2, and 3. Section 312.23(a)(7)--Chemistry, manufacturing, and control information. Section 312.23(a)(7)(iv)(a),(b),(c)--A description of the drug substance, a list of all components, and any placebo used. Section 312.23(a)(7)(iv)(d)--Labeling: Copies of labels and labeling to be provided each investigator. Section 312.23(a)(7)(iv)(e)--Environmental impact analysis regarding drug manufacturing and use. Section 312.23(a)(8)--Pharmacological and toxicology information. Section 312.23(a)(9)--Previous human experience with the investigational drug. Section 312.23(a)(10)--Additional information. Section 312.23(a)(11)--Relevant information. Section 312.23(f)--Identification of exception from informed consent. Section 312.30--Protocol amendments. Sec. 312.30(a)--New protocol Sec. 312.30(b)--Changes in protocol Sec. 312.30(c)--New investigator. Sec. 312.30(d)--Content and format. Sec. 312.30(e)--Frequency. Section 312.31--Information amendments. Sec. 312.31(b)--Content and format. -- Chemistry, toxicology, or technical information. Section 312.32--Safety reports. Sec. 312.32(c)(1)--Written reports to FDA and to investigators. Sec. 312.32(c)(2)--Telephone reports to FDA for fatal or life- threatening experience. Sec. 312.32(c)(3)--Format or frequency. Sec. 312.32(d)--Followup submissions. Section 312.33--Annual reports. Sec. 312.33(a)--Individual study information. Sec. 312.33(b)--Summary information. Sec. 312.33(b)(1)--Adverse experiences. Sec. 312.33(b)(2)--Safety report summary. Sec. 312.33(b)(3)--List of fatalities and causes of death. Sec. 312.33(b)(4)--List of discontinuing subjects. Sec. 312.33 (b)(5)--Drug action. Sec. 312.33 (b)(6)--Preclinical studies and findings. Sec. 312.33 (b)(7)--Significant changes. Sec. 312.33(c)--Next year general investigational plan. Sec. 312.33(d)--Brochure revision. Sec. 312.33(e)--Phase I protocol modifications. Sec. 312.33(f)--Foreign marketing developments. Section 312.38(b) and (c)--Notification of withdrawal of an IND. Section 312.41--Comment and advice on an IND. Estimates for the information collection in this requirement are included under Sec. 312.23. Section 312.42--Sponsor requests that a clinical hold be removed, and submits a complete response to the issues identified in the clinical hold order. Section 312.44(c) and (d)--Opportunity for sponsor response to FDA when IND is terminated. Section 312.45(a) and (b)--Sponsor request for, or response to, an inactive status determination of an IND. Section 312.47--Meetings, including ``End-of-Phase 2'' meetings and ``Pre-NDA'' meetings. Section 312.48--Dispute resolution. Estimates for the information collection in this requirement are included under Sec. 312.47. Section 312.53(c)--Investigator information. Investigator report (Form FDA-1572) and narrative; Investigator's background information; Phase 1 outline of planned investigation and Phase 2 outline of study protocol. Section 312.54(a) and (b)--Sponsor submissions concerning investigations involving an exception from informed consent under Sec. 50.24. Sec. 312.55(b)--Sponsor reports to investigators on new observations, especially adverse reactions and safe use. Only ``new observations'' are estimated under this section; investigator brochures are included under Sec. 312.23. Section 312.56(b), (c), and (d)--Sponsor monitoring of all clinical investigations, investigators, and drug safety; notification to FDA and others. Section 312.58(a)--Sponsor's submission of records to FDA on request. Section 312.64--Investigator reports to the sponsor. Sec. 312.64(a)--Progress reports. Sec. 312.64(b)--Safety reports Sec. 312.64(c)--Final reports. Sec. 312.64(d)--Financial disclosure [[Page 11451]] reports. Section 312.66--Investigator reports to institutional review board (IRB). Estimates for the information collection in this requirement are included under Sec. 312.53. Section 312.70--Investigator disqualification; opportunity to respond to FDA. Section 312.83--Sponsor submission of treatment protocol. Estimates for this requirement are included under Sec. 312.320. Section 312.85--Sponsors conducting phase 4 studies. Estimates for the information collection in this requirement are included under Sec. 312.23, and under Sec. Sec. 314.50, 314.70, and 314.81 in OMB control number 0910-0001. Section 312.110(b)--Requests to export an investigational drug. Section 312.120--Submissions related to foreign clinical studies not conducted under an IND. Section 312.130--Requests for disclosable information in an IND and from investigations involving an exception from informed consent under Sec. 50.24. Sections 312.310(b); 312.305(b)--Submissions related to expanded access and treatment of an individual patient. Section 312.310(d)--Submissions related to emergency use of an investigational new drug. Sections 312.315(c); 312.305(b)--Submissions related to expanded access and treatment of an intermediate-size patient population. Section 312.320--Submissions related to a treatment IND or treatment protocol. II. Recordkeeping Requirements Section 312.52(a)--Transfer of obligations to a contract research organization. Section 312.57--Sponsor recordkeeping on the investigational drug. Section 312.59--Sponsor recordkeeping of disposition of unused supply of drugs. Estimates for the information collection in this requirement are included under Sec. 312.57. Section 312.62(a)--Investigator recordkeeping of disposition of drugs. Section 312.62(b)--Investigator recordkeeping of case histories of individuals. Section 312.120(d)--Recordkeeping requirements for submissions related to foreign clinical studies not conducted under an IND. Estimates for the information collection in this requirement are included under Sec. 312.57. Section 312.160(a)(3)--Records pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests. Section 312.160(c)--Shipper records of alternative disposition of unused drugs. In the Federal Register of November 5, 2014 (79 FR 65663), FDA published a 60-day notice requesting public comment on the proposed collection of information. FDA received 24 comments, however, these comments did not address the information collection. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Reporting Burden for Human Drugs \1\ ---------------------------------------------------------------------------------------------------------------- Number of 21 CFR section Number of responses per Total annual Average burden Total hours respondents respondent responses per response ---------------------------------------------------------------------------------------------------------------- 312.2(e), Requests for FDA 800 1 800 24 19,200 advice on the applicability of part 312 to a planned clinical investigation.................. 312.8, Requests to charge for an 56 1.25 70 48 3,360 investigational drug........... 312.10, Requests to waive a 50 1.76 88 24 2,112 requirement in part 312........ 312.23(a) through (f), IND 1,689 1.57 2,648 1,600 4,236,800 content and format (including Form FDA 1571)................. 312.30(a) through (e), Protocol 3,739 5.77 21,588 284 6,130,992 amendments..................... 312.31 (b), Information 4,537 3.39 15,377 100 1,537,700 amendments..................... 312.32(c) and (d), IND Safety 755 24.28 18,332 32 586,624 reports........................ 312.33(a) through (f), IND 2,877 2.76 7,953 360 2,863,080 Annual reports................. 312.38(b) and (c), Notifications 862 1.54 1,328 28 37,184 of withdrawal of an IND........ 312.42, Sponsor requests that a 158 1.30 205 284 58,220 clinical hold be removed, including sponsor submission of a complete response to the issues identified in the clinical hold order............ 312.44(c) and (d), Sponsor 12 1 12 16 192 responses to FDA when IND is terminated..................... 312.45(a) and (b), Sponsor 260 1.73 451 12 5,412 requests for or responses to an inactive status determination of an IND by FDA............... 312.47, Meetings, including 225 1.86 419 160 67,040 ``End-of-Phase 2'' meetings and ``Pre-NDA'' meetings........... 312.53(c), Investigator reports 1,444 8.38 12,087 80 966,960 submitted to the sponsor, including Form FDA 1572, curriculum vitae, clinical protocol, and financial disclosure. (Third party disclosure).................... 312.54(a), Sponsor submissions 7 5 35 48 1,680 to FDA concerning investigations involving an exception from informed consent under 21 CFR 50.24............. 312.54(b), Sponsor notifications 7 1 7 48 336 to FDA and others concerning an IRB determination that it cannot approve research because it does not meet the criteria in the exception from informed consent in Sec. 50.24(a). (Includes third party disclosure).................... 312.55(a), Investigator 590 3.50 2,067 48 99,216 brochures submitted by the sponsor to each investigator. (Third party disclosure)....... [[Page 11452]] 312.55(b), Sponsor reports to 590 3.50 2,067 48 99,216 investigators on new observations, especially adverse reactions and safe use. (Third party disclosure)....... 312.56(b),(c), and (d), Sponsor 3,584 6.52 23,355 80 1,868,400 notifications to FDA and others resulting from: (1) The sponsor's monitoring of all clinical investigations and determining that an investigator is not in compliance with the investigation agreements; (2) the sponsor's review and evaluation of the evidence relating to the safety and effectiveness of the investigational drug; and (3) the sponsor's determination that the investigational drug presents an unreasonable and significant risk to subjects. (Includes third party disclosure).................... 312.58(a), Sponsor's submissions 60 1 60 8 480 of clinical investigation records to FDA on request during FDA inspections......... 312.64, Investigator reports to 1,444 1 1,444 24 34,656 the sponsor, including progress reports, safety reports, final reports, and financial disclosure reports. (Third party disclosure).............. 312.70, During the 4 1 4 40 160 disqualification process of a clinical investigator by FDA, the number of investigator responses or requests to FDA following FDA's notification to an investigator of its failure to comply with investigation requirements................... 312.110(b)(4) and (b)(5), 11 26.28 289 75 21,675 Written certifications and written statements submitted to FDA relating to the export of an investigational drug........ 312.120(b), Submissions to FDA 1,414 8.63 12,198 32 390,336 of ``supporting information'' related to the use of foreign clinical studies not conducted under an IND................... 312.120(c), Waiver requests 35 2.34 82 24 1,968 submitted to FDA related to the use of foreign clinical studies not conducted under an IND..... 312.130, Requests for 3 1 3 8 24 disclosable information in an IND and for investigations involving an exception from informed consent under Sec. 50.24.......................... 312.310(b) and 312.305(b), 228 1.76 401 8 3,208 Submissions related to expanded access and treatment of an individual patient............. 312.310(d), Submissions related 410 2.19 899 16 14,384 to emergency use of an investigational new drug....... 312.315(c) and 312.305(b), 44 7.07 311 120 37,320 Submissions related to expanded access and treatment of an intermediate-size patient population..................... 312.320(b), Submissions related 12 12.67 152 300 45,600 to a treatment IND or treatment protocol....................... ------------------------------------------------------------------------------- Total....................... .............. .............. .............. .............. 19,134,039 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 2--Estimated Annual Recordkeeping Burden for Human Drugs \1\ ---------------------------------------------------------------------------------------------------------------- Number of Average burden 21 CFR section Number of records per Total annual per Total hours recordkeepers recordkeeper records recordkeeping ---------------------------------------------------------------------------------------------------------------- 312.52(a), Sponsor records for 335 1.50 503 2 1,006 the transfer of obligations to a contract research organization................... 312.57, Sponsor recordkeeping 1,689 1 1,689 100 168,900 showing the receipt, shipment, or other disposition of the investigational drug, and any financial interests............ 312.62(a), Investigator 1,444 1 1,444 40 57,760 recordkeeping of the disposition of drugs........... 312.62(b), Investigator 1,444 1 1,444 40 57,760 recordkeeping of case histories of individuals................. 312.160(a)(3), Records 547 1.40 782 * 0.50 391 pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests.............. 312.160(c), Shipper records of 547 1.40 782 * 0.50 391 alternative disposition of unused drugs................... ------------------------------------------------------------------------------- [[Page 11453]] Total....................... .............. .............. .............. .............. 286,190 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. * Thirty (30) minutes. Table 3--Estimated Annual Reporting Burden for Biologics \1\ ---------------------------------------------------------------------------------------------------------------- Number of 21 CFR section Number of responses per Total annual Average burden Total hours respondents respondent responses per response ---------------------------------------------------------------------------------------------------------------- 312.2(e), Requests for FDA 217 1.18 255 24 6,120 advice on the applicability of part 312 to a planned clinical investigation.................. 312.8, Requests to charge for an 20 1.50 30 48 1,440 investigational drug........... 312.10, Requests to waive a 2 1 2 24 48 requirement in part 312........ 312.23(a) through (f), IND 335 1.35 452 1,600 723,200 content and format............. 312.30(a) through (e), Protocol 694 5.84 4,050 284 1,150,200 amendments..................... 312.31(b), Information 77 2.43 187 100 18,700 amendments..................... 312.32(c) and (d), IND Safety 161 8.83 1,421 32 45,472 reports........................ 312.33(a) through (f), IND 745 2.14 1,595 360 574,200 Annual reports................. 312.38(b) and (c), Notifications 134 1.69 227 28 6,356 of withdrawal of an IND........ 312.42, Sponsor requests that a 67 1.30 87 284 24,708 clinical hold be removed, including sponsor submission of a complete response to the issues identified in the clinical hold order............ 312.44(c) and (d), Sponsor 34 1.15 39 16 624 responses to FDA when IND is terminated..................... 312.45(a) and (b), Sponsor 55 1.38 76 12 912 requests for or responses to an inactive status determination of an IND by FDA............... 312.47, Meetings, including 88 1.75 154 160 24,640 ``End-of-Phase 2'' meetings and ``Pre-NDA'' meetings........... 312.53(c), Investigator reports 453 6.33 2,869 80 229,520 submitted to the sponsor, including Form FDA-1572, curriculum vitae, clinical protocol, and financial disclosure..................... 312.54(a), Sponsor submissions 1 1 1 48 48 to FDA concerning investigations involving an exception from informed consent under Sec. 50.24............. 312.54(b), Sponsor notifications 1 1 1 48 48 to FDA and others concerning an IRB determination that it cannot approve research because it does not meet the criteria in the exception from informed consent in Sec. 50.24(a)..... 312.55(a), Number of 239 1.91 457 48 21,936 investigator brochures submitted by the sponsor to each investigator.............. 312.55(b), Number of sponsor 243 4.95 1,203 48 57,744 reports to investigators on new observations, especially adverse reactions and safe use. 312.56(b), (c), and (d), Sponsor 108 2.21 239 80 19,120 notifications to FDA and others resulting from: (1) The sponsor's monitoring of all clinical investigations and determining that an investigator is not in compliance with the investigation agreements; (2) the sponsor's review and evaluation of the evidence relating to the safety and effectiveness of the investigational drug; and (3) the sponsor's determination that the investigational drug presents an unreasonable and significant risk to subjects... 312.58(a), Number of sponsor's 7 1 7 8 56 submissions of clinical investigation records to FDA on request during FDA inspections. 312.64, Number of investigator 2,728 3.82 10,411 24 249,864 reports to the sponsor, including progress reports, safety reports, final reports, and financial disclosure reports........................ 312.70, During the 5 1 5 40 200 disqualification process of a clinical investigator by FDA, the number of investigator responses or requests to FDA following FDA's notification to an investigator of its failure to comply with investigation requirements................... 312.110(b)(4) and (b)(5), Number 18 1 18 75 1,350 of written certifications and written statements submitted to FDA relating to the export of an investigational drug........ [[Page 11454]] 312.120(b), Number of 280 9.82 2,750 32 88,000 submissions to FDA of ``supporting information'' related to the use of foreign clinical studies not conducted under an IND................... 312.120(c), Number of waiver 7 2.29 16 24 384 requests submitted to FDA related to the use of foreign clinical studies not conducted under an IND................... 312.130, Number of requests for 350 1.34 470 8 3,760 disclosable information in an IND and for investigations involving an exception from informed consent under Sec. 50.24.......................... 312.310(b) and 312.305(b), 78 1.08 84 8 672 Number of submissions related to expanded access and treatment of an individual patient........................ 312.310(d), Number of 76 2.76 210 16 3,360 submissions related to emergency use of an investigational new drug....... 312.315(c) and 312.305(b), 9 1 9 120 1,080 Number of submissions related to expanded access and treatment of an intermediate- size patient population........ 312.320(b), Number of 1 1 1 300 300 submissions related to a treatment IND or treatment protocol....................... ------------------------------------------------------------------------------- Total....................... .............. .............. .............. .............. 3,254,062 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 4--Estimated Annual Recordkeeping Burden for Biologics \1\ ---------------------------------------------------------------------------------------------------------------- Number of Average burden 21 CFR section Number of records per Total annual per Total hours recordkeepers recordkeeper records recordkeeping ---------------------------------------------------------------------------------------------------------------- 312.52(a), Sponsor records for 75 1.40 105 2 210 the transfer of obligations to a contract research organization................... 312.57, Sponsor recordkeeping 335 2.70 904 100 90,400 showing the receipt, shipment, or other disposition of the investigational drug, and any financial interests............ 312.62(a), Investigator 453 1 453 40 18,120 recordkeeping of the disposition of drugs........... 312.62(b), Investigator 453 1 453 40 18,120 recordkeeping of case histories of individuals................. 312.160(a)(3), Records 111 1.40 155 * 0.50 78 pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests.............. 312.160(c), Shipper records of 111 1.40 155 * 0.50 78 alternative disposition of unused drugs................... ------------------------------------------------------------------------------- Total....................... .............. .............. .............. .............. 127,006 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. * Thirty (30) minutes. Dated: February 24, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015-04379 Filed 3-2-15; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 80, No. 41 / Tuesday, March 3, 2015 / Notices 11449
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1—Continued
Number of
Number of Total annual
21 CFR section responses per Average burden per response Total hours
respondents responses
respondent
610.47(a)(3) ...................................... 1,945 12.03 23,400 0.17 (10 minutes) ............................. 3,978
610.47(b)(3) ...................................... 4,961 0.41 2,050 1 ....................................................... 2,050
630.6(a) 3 ........................................... 648 668.72 433,333 0.08 (5 minutes) ............................... 34,667
630.6(a) 4 ........................................... 84 53.57 4,500 1.5 (90 minutes) ............................... 6,750
630.6(d)(1) ........................................ 63 35.71 2,250 1 ....................................................... 2,250
Total ........................................... ........................ ........................ ........................ ........................................................... 61,043
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Five percent of establishments that fall under CLIA that transfuse blood and components and FDA-registered blood establishments (0.05 ×
4,961 + 2,361 = 366).
3 Notification of donors determined not to be eligible for donation based on failure to satisfy eligibility criteria.
4 Notification of donors deferred based on reactive test results for evidence of infection due to communicable disease agents.
Dated: February 25, 2015. Spring, MD 20993–0002, PRAStaff@ revisions of clinical investigation plans,
Leslie Kux, fda.hhs.gov. and information on a drug’s safety or
Associate Commissioner for Policy. SUPPLEMENTARY INFORMATION: In effectiveness. In addition, the sponsor is
[FR Doc. 2015–04381 Filed 3–2–15; 8:45 am] compliance with 44 U.S.C. 3507, FDA required to give FDA an annual
BILLING CODE 4164–01–P has submitted the following proposed summary of the previous year’s clinical
collection of information to OMB for experience.
review and clearance. Submissions are reviewed by medical
DEPARTMENT OF HEALTH AND officers and other Agency scientific
HUMAN SERVICES Investigational New Drug (IND) reviewers assigned responsibility for
Regulations—21 CFR Part 312 (OMB overseeing the specific study. The IND
Food and Drug Administration Control Number 0910–0014)—Extension regulations also contain recordkeeping
[Docket No. FDA–2014–N–1721] FDA is requesting OMB approval for requirements that pertain to the
the reporting and recordkeeping responsibilities of sponsors and
Agency Information Collection requirements contained in FDA investigators. The detail and complexity
Activities; Submission for Office of regulations entitled ‘‘Investigational of these requirements are dictated by the
Management and Budget Review; New Drug Application’’ in part 312 (21 scientific procedures and human subject
Comment Request; Investigational CFR part 312). Part 312 implements safeguards that must be followed in the
New Drug Applications provisions of section 505(i) of the clinical tests of investigational new
Federal Food, Drug, and Cosmetic Act drugs.
AGENCY: Food and Drug Administration,
(the FD&C Act) (21 U.S.C. 355(i)) to The IND information collection
HHS.
issue regulations under which the requirements provide the means by
ACTION: Notice. which FDA can monitor the clinical
clinical investigation of the safety and
SUMMARY: The Food and Drug effectiveness of unapproved new drugs investigation of the safety and
Administration (FDA) is announcing and biological products can be effectiveness of unapproved new drugs
that a proposed collection of conducted. and biological products, including the
information has been submitted to the FDA is charged with implementing following: (1) Monitor the safety of
Office of Management and Budget statutory requirements that drug ongoing clinical investigations; (2)
(OMB) for review and clearance under products marketed in the United States determine whether the clinical testing of
the Paperwork Reduction Act of 1995. be shown to be safe and effective, a drug should be authorized; (3) ensure
DATES: Fax written comments on the properly manufactured, and properly production of reliable data on the
collection of information by April 2, labeled for their intended uses. Section metabolism and pharmacological action
2015. 505(a) of the FD&C Act provides that a of the drug in humans; (4) obtain timely
new drug may not be introduced or information on adverse reactions to the
ADDRESSES: To ensure that comments on delivered for introduction into interstate drug; (5) obtain information on side
the information collection are received, commerce in the United States unless effects associated with increasing doses;
OMB recommends that written FDA has previously approved a new (6) obtain information on the drug’s
comments be faxed to the Office of drug application (NDA). FDA approves effectiveness; (7) ensure the design of
Information and Regulatory Affairs, an NDA only if the sponsor of the well-controlled, scientifically valid
OMB, Attn: FDA Desk Officer, FAX: application first demonstrates that the studies; and (8) obtain other information
202–395–7285, or emailed to oira_ drug is safe and effective for the pertinent to determining whether
submission@omb.eop.gov. All conditions prescribed, recommended, or clinical testing should be continued,
comments should be identified with the suggested in the product’s labeling. and information related to the
OMB control number 0910–0014. Also
mstockstill on DSK4VPTVN1PROD with NOTICES
Proof must consist, in part, of adequate protection of human subjects. Without
include the FDA docket number found and well-controlled studies, including the information provided by industry as
in brackets in the heading of this studies in humans, that are conducted required under the IND regulations,
document. by qualified experts. The IND FDA cannot authorize or monitor the
FOR FURTHER INFORMATION CONTACT: FDA regulations establish reporting clinical investigations which must be
PRA Staff, Office of Operations, Food requirements that include an initial conducted prior to authorizing the sale
and Drug Administration, 8455 application as well as amendments to and general use of new drugs. These
Colesville Rd., COLE–14526, Silver that application, reports on significant reports enable FDA to monitor a study’s
VerDate Sep<11>2014 19:24 Mar 02, 2015 Jkt 235001 PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\03MRN1.SGM 03MRN1](https://thefederalregister.org/doc/80_FR_11490/page/1.svg)
![11454 Federal Register / Vol. 80, No. 41 / Tuesday, March 3, 2015 / Notices
TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN FOR BIOLOGICS 1—Continued
Number of Average
Number of Total annual
21 CFR section responses per burden per Total hours
respondents responses
respondent response
312.120(b), Number of submissions to FDA of ‘‘sup-
porting information’’ related to the use of foreign clin-
ical studies not conducted under an IND ....................... 280 9.82 2,750 32 88,000
312.120(c), Number of waiver requests submitted to FDA
related to the use of foreign clinical studies not con-
ducted under an IND ...................................................... 7 2.29 16 24 384
312.130, Number of requests for disclosable information
in an IND and for investigations involving an exception
from informed consent under § 50.24 ............................ 350 1.34 470 8 3,760
312.310(b) and 312.305(b), Number of submissions re-
lated to expanded access and treatment of an indi-
vidual patient .................................................................. 78 1.08 84 8 672
312.310(d), Number of submissions related to emer-
gency use of an investigational new drug ..................... 76 2.76 210 16 3,360
312.315(c) and 312.305(b), Number of submissions re-
lated to expanded access and treatment of an inter-
mediate-size patient population ..................................... 9 1 9 120 1,080
312.320(b), Number of submissions related to a treat-
ment IND or treatment protocol ..................................... 1 1 1 300 300
Total ............................................................................ ........................ .......................... ........................ ........................ 3,254,062
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 4—ESTIMATED ANNUAL RECORDKEEPING BURDEN FOR BIOLOGICS 1
Number of Average
Number of Total annual
21 CFR section records per burden per Total hours
recordkeepers records
recordkeeper recordkeeping
312.52(a), Sponsor records for the transfer of obligations
to a contract research organization ............................... 75 1.40 105 2 210
312.57, Sponsor recordkeeping showing the receipt,
shipment, or other disposition of the investigational
drug, and any financial interests .................................... 335 2.70 904 100 90,400
312.62(a), Investigator recordkeeping of the disposition
of drugs .......................................................................... 453 1 453 40 18,120
312.62(b), Investigator recordkeeping of case histories of
individuals ....................................................................... 453 1 453 40 18,120
312.160(a)(3), Records pertaining to the shipment of
drugs for investigational use in laboratory research ani-
mals or in vitro tests ....................................................... 111 1.40 155 * 0.50 78
312.160(c), Shipper records of alternative disposition of
unused drugs .................................................................. 111 1.40 155 * 0.50 78
Total ............................................................................ ........................ .......................... ........................ ........................ 127,006
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
* Thirty (30) minutes.
Dated: February 24, 2015. DEPARTMENT OF HEALTH AND workshop to discuss dystrophin protein
Leslie Kux, HUMAN SERVICES quantification methodologies for human
Associate Commissioner for Policy. tissue. This workshop is being
Food and Drug Administration cosponsored by the National Institutes
[FR Doc. 2015–04379 Filed 3–2–15; 8:45 am]
BILLING CODE 4164–01–P [Docket No. FDA–2015–N–0430] of Health (NIH). The purpose of the
workshop is to discuss currently
Measuring Dystrophin in available methodologies and to identify
Dystrophinopathy Patients and scientific knowledge gaps and
Interpreting the Data; Public Scientific opportunities for improving dystrophin
Workshop; Request for Comments protein detection in the context of drug
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY: Food and Drug Administration, development. The intended audiences
HHS. for this workshop are scientists and
clinicians involved in the acquisition,
ACTION:Notice of public scientific
measurement, and analysis of proteins
workshop; request for comments.
associated with Duchenne Muscular
The Food and Drug Administration Dystrophy (DMD).
(FDA) is announcing a public scientific
VerDate Sep<11>2014 19:24 Mar 02, 2015 Jkt 235001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\03MRN1.SGM 03MRN1](https://thefederalregister.org/doc/80_FR_11490/page/6.svg)
Document Created: 2015-12-18 11:55:40
Document Modified: 2015-12-18 11:55:40
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Fax written comments on the collection of information by April 2, 2015. | |
| Contact | FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected] | |
| FR Citation | 80 FR 11449 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR